晚期黑色素瘤CheckMate 067研究4年随访结果
CheckMate 067三期随机对照试验4年随访,945例晚期黑色素瘤患者接受纳武利尤单抗+伊匹木单抗、纳武利尤单抗单药或伊匹木单抗单药一线治疗,双药联合及单药均较伊匹木单抗显著改善总生存和无进展生存,联合组3-4级治疗相关不良事件发生率为59%。
要点
- 联合组3-4级治疗相关不良事件59%,以腹泻和脂肪酶升高常见
核心结论
- 一线纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药均可在晚期黑色素瘤中实现持久生存获益。
研究设计与样本
- 三期随机对照试验,945例初治不可切除III/IV期黑色素瘤按1:1:1随机分组。
- 双药组314例,纳武利尤单抗组316例,伊匹木单抗组315例,按PD-L1、BRAF状态和转移分期分层。
主要发现
- 双药组3-4级治疗相关不良事件185/313(59%),纳武利尤单抗组70/313(22%),伊匹木单抗组86/311(28%)。
关键数值与推荐
- 双药组最常见3级不良事件为腹泻(29/313,9%),纳武利尤单抗组为腹泻(9/313,3%),伊匹木单抗组为结肠炎(23/311,7%)。
- 三组最常见4级不良事件均为脂肪酶升高,双药组15/313(5%),纳武利尤单抗组10/313(3%),伊匹木单抗组4/311(1%)。
- 研究总计4例治疗相关死亡:双药组2例(心肌病、肝坏死),纳武利尤单抗组1例(中性粒细胞减少),伊匹木单抗组1例(结肠穿孔)。
临床怎么用
- 对初治晚期黑色素瘤可考虑一线纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药,联合方案需警惕3-4级不良事件。
- 双药联合组腹泻和脂肪酶升高需重点监测,纳武利尤单抗单药组安全性相对更好。
局限性
- 4年随访未分析严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. METHODS: In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505. FINDINGS: Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis. INTERPRETATION: The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma. FUNDING: Bristol-Myers Squibb.
引用
- Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018. PMID: 30361170. doi:10.1016/S1470-2045(18)30700-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。